SCHEMBL1619293

SCHEMBL1619293

Cc1ccc(CSc2nc(N3C=COCC3)c3ncn(C)c3n2)cc1[N+](=O)[O-]

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
MAPT P10636 5/20 0.34
APLNR P35414 2/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
GAA P10253 2/20 0.32
SLC29A1 Q99808 1/20 0.32
KDM4E B2RXH2 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
LMNA P02545 3/20 0.31
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31
GFER P55789 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130128 0.90 ALDH1A1 (0.47) ALDH1A1MAPTHTR1AHTR1DHTR1B
SCHEMBL100664 0.89 LMNA (0.45) ALDH1A1MAPTGAALMNAPOLB
SCHEMBL1620604 0.86 PIK3CA (0.32)
SCHEMBL100634 0.81 LMNA (0.44) ALDH1A1MAPTGAALMNAPOLB
SCHEMBL171412 0.81 ALDH1A1 (0.45) ALDH1A1MAPTGAALMNAPOLB
SCHEMBL101563 0.80 ALDH1A1 (0.40) ALDH1A1SLC29A1HPGD
SCHEMBL97446 0.79 ALDH1A1 (0.40) ALDH1A1MAPTKDM4ELMNAHPGD
SCHEMBL1620970 0.79 ALDH1A1 (0.41) ALDH1A1MAPTSLC29A1KDM4EAPOBEC3G
SCHEMBL129813 0.79 L3MBTL1 (0.32) ALDH1A1MAPTGAALMNAGFER
SCHEMBL1679227 0.78 ALDH1A1 (0.32) ALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME PNP, TYMP, DPYD ALDH1A1 336/4885MAPT 4571/4885APLNR 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.